RP-HPLC Method Development and Validation for Abiraterone and Niraparib estimation in Tablet Dosage Form for Cancer Treatment

Abstract

A simple, Accurate, precise method was developed for the simultaneous estimation of the Abiraterone and Niraparib in Tablet dosage form. Chromatogram was run through Kromasil 250 x 4.6 mm, 5. Mobile phase containing Buffer 0.01N potassium dihydrogen orthophosphate: Acetonitrile taken in the ratio 60:40 was pumped through column at a flow rate of 1 ml/min. Buffer used in this method was Potassium dihydrogen orthophosphate buffer. Temperature was maintained at 30°C. Optimized wavelength selected was 260.0 nm. Retention time of Abiraterone and Niraparib were found to be 2.125 min and 2.638 min. %RSD of the Abiraterone and Niraparib were and found to be 0.5 and 0.9 respectively. %Recovery was obtained as 99.51% and 99.61% for Abiraterone and Niraparib respectively. LOD, LOQ values obtained from regression equations of Abiraterone and Niraparib were 0.65, 1.96 and 0.03, 0.10 respectively. Regression equation of Abiraterone is y = 4033.6x + 173.05, and y = 10742x + 173.05 of Niraparib.